These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37040827)

  • 1. Diabetes-related outcomes with basal-bolus vs. premixed insulin among veterans with type 2 diabetes: A single institutional retrospective study.
    Bai R; Batra K; Yap C; Izuora K
    Am J Med Sci; 2023 Jul; 366(1):38-43. PubMed ID: 37040827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized intensification of insulin therapy in type 2 diabetes - does a basal-bolus regimen suit all patients?
    Giugliano D; Sieradzki J; Stefanski A; Gentilella R
    Curr Med Res Opin; 2016 Aug; 32(8):1425-34. PubMed ID: 27126277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of diabetic ketoacidosis, severe hypoglycemia and glycemic control among children and young adults with type 1 diabetes mellitus treated with premixed versus basal-bolus insulin therapy.
    Chou WY; Li YR; Chan WK; Chen ST
    Biomed J; 2018 Dec; 41(6):348-355. PubMed ID: 30709576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study).
    Bajaj HS; Venn K; Ye C; Patrick A; Kalra S; Khandwala H; Aslam N; Twum-Barima D; Aronson R
    Diabetes Care; 2017 Feb; 40(2):194-200. PubMed ID: 27913575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections.
    Riddle MC; Rosenstock J; Vlajnic A; Gao L
    Diabetes Obes Metab; 2014 May; 16(5):396-402. PubMed ID: 24118931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
    Giugliano D; Chiodini P; Maiorino MI; Bellastella G; Esposito K
    Endocrine; 2016 Mar; 51(3):417-28. PubMed ID: 26281001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoglycemic events and glycemic control effects between NPH and premixed insulin in patients with type 2 diabetes mellitus: A real-world experience at a comprehensive specialized hospital in Ethiopia.
    Sendekie AK; Netere AK; Belachew EA
    PLoS One; 2022; 17(9):e0275032. PubMed ID: 36149907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial.
    Jia W; Xiao X; Ji Q; Ahn KJ; Chuang LM; Bao Y; Pang C; Chen L; Gao F; Tu Y; Li P; Yang J
    Lancet Diabetes Endocrinol; 2015 Apr; 3(4):254-62. PubMed ID: 25754414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design.
    Levin PA; Zhang Q; Mersey JH; Lee FY; Bromberger LA; Bhushan M; Bhushan R
    Clin Ther; 2011 Jul; 33(7):841-50. PubMed ID: 21719107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of basal and premixed insulin on glycemic control in type 2 diabetes patients based on multicenter prospective real-world data.
    Peng Y; Xu P; Shi J; Zhang Y; Wang S; Zheng Q; Wang Y; Ke T; Li L; Zhao D; Dai Y; Dong Q; Ji B; Xu F; Gu W; Wang W
    J Diabetes; 2022 Feb; 14(2):134-143. PubMed ID: 35023626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study.
    Fritsche A; Larbig M; Owens D; Häring HU;
    Diabetes Obes Metab; 2010 Feb; 12(2):115-23. PubMed ID: 20092584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Post-hoc analyses of type 2 diabetes patients switch from premixed insulin regimen to basal insulin plus oral hypoglycemic agents regimen].
    Bu S; Guo XH; Yang WY; Lu GZ; Yang ZJ; Ren TT; Gao Y
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3115-8. PubMed ID: 18269868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Basal Insulin-Based Treatment Versus Twice-Daily Premixed Insulin After Short-Term Intensive Insulin Therapy in Patients with Type 2 Diabetes Mellitus in China: Study Protocol for a Randomized Controlled Trial (BEYOND V).
    Liu J; Jiang X; Xu B; Wang G; Cui N; Zhang X; Liu J; Mu Y; Guo L
    Adv Ther; 2020 Apr; 37(4):1675-1687. PubMed ID: 32130661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus.
    Alemzadeh R; Berhe T; Wyatt DT
    Pediatrics; 2005 May; 115(5):1320-4. PubMed ID: 15867042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study.
    Zhang B; Zhao J; Yang W;
    Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27667797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of insulin treatment in type 2 diabetes using a new index called glucose safety control index.
    Cai XL; Luo YY; Han XY; Ji LN
    Chin Med J (Engl); 2013 Nov; 126(21):4166-74. PubMed ID: 24229692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.